Agree the share price is cheap but there is more than one way to stop the bleeding. It can be a call to arms: “to the barricade!” with purchase orders but I’ll mention in passing over 4 million shares were borrowed short an hour before close, returned around the close. You can do a lot of damage with that volume of shares. Without news that turns the tide it’s easy to push the price down. Dedicated longs have tried to absorb the onslaught for a long time. I’ve lowered my average significantly but under strict orders from the better half to cease and desist. On the bright side there is a flip side we should remind ourselves of…I have mentioned before my sense is that extant shares are moving inexorably to people with faith and commitment….Walsh knows something about that. I’m sure the flippers are out there but many are holding on to their poker chips. When they light up the Saturn rocket I suspect they are not going to let go of those shares for cheap. Sold too soon is a lesson few learn, right up there with lacking the patience for a situation to develop. Borrowed shares must be bought back and when people see a rocket going to Tomorrowland they will want a seat and will have to pay for the privilege…tides move in two directions.
The OTHER way to help reverse the tide is for the Company to show up with something palpable. I think it will come in due course so I will wait for the game changing event, but NOW would be a good time to deliver on the change in communication strategy they talked about. Put some color on things; as mightycydy pointed out…why are we needing to do a preclinical study for NASH? Explain it…there must be a reason…one was already done and the mice liked how they felt in the treatment group…and we have something more valuable in a human study. Those mice sipping high fructose, high fat cocktails are not the same as positive data from a human trial. If we are going back to the mice for comment, explain it.
Right up there with truly market moving news quality communications would help…I hate being reduced to guessing, conjecture and reading entrails to divine what is going on.
Introduction to Scilex Holding Company
Pioneering company Scilex Holding Company (Nasdaq: SCLX) is concentrated on the development and marketing of non-opioid pain management solutions. Dedicated to enhancing patient quality of life, Scilex seeks to lead the worldwide pain management solution market. To guarantee responsible pharmaceutical development, the company operates under tight social, environmental, financial, and ethical standards.
Overview of the Master Distributor Agreement
B... Continue Reading
Overview of Above Food's Strategic Acquisition
Leading food company known for its vertically integrated supply chain, Above Food Ingredients Inc. (Nasdaq: ABVE, ABVE.W), has said a major US expansion with the acquisition of The Redwood Group, LLC's Specialty Crop Food Ingredients Division. valued at $34 million, this calculated action consists of 5.6 million recently issued common shares of Above Food combined with $8.1 million in cash. Following usual closing criteria and final adjus... Continue Reading
Hurco and Kawasaki Robotics Join Forces
Leader in CNC machine and control technology Hurco Companies, Inc. (Nasdaq: HURC) has announced a strategic alliance with respected producer of industrial robotics and automation systems Kawasaki Robotics (USA, Inc.). Leveraging over 50 years of Hurco's knowledge in CNC machine tools and controls and Kawasaki's vast industrial robotics expertise, this collaboration combines the strengths of both companies. Taken together, they seek to provide tu... Continue Reading
Introduction to Mangoceuticals’ Innovative Approach
With the release of its recently created DEA-approved telemedicine operating system, Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx") has reached a turning point. The company's goal of providing creative men's health and wellness products—including solutions for erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies—is much advanced by this development. MangoRx is dedicated ... Continue Reading
Category: StocksTotal Views: 209 By : Ryan HughesUpdated: 08-11-2024
Introduction to ANEW Medical, Inc.
Pioneering biopharmaceutical company ANEW Medical, Inc. (NASDAQ: WENA) is committed to create creative, disease-modifying treatments aiming at the brain and central nervous system (CNS). Among the most difficult neurodegenerative diseases the company targets are Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), and several types of cancer. By means of innovative research and development, ANEW Medical seeks to fulfill major unmet medical ... Continue Reading
Senior Convertible Debt Agreement with Accredited Institutional Investor
Webuy Global Ltd. (Nasdaq: WBUY) announced a new senior convertible debt agreement with an initial principal amount of $2 million. The company could be able to get an extra $4 million, subject to mutual agreement with the accredited institutional investor engaged. Set at $0.213 per share, which is 150% of the company's Class A ordinary shares' volume-weighted average price (VWAP) on the trading day before the not... Continue Reading
The Strategic Importance of Gevo's Net-Zero 1 Facility
Based on a key analysis by Charles River Associates (CRA), Gevo, Inc. (NASDAQ: GEVO) has revealed the major environmental and financial advantages linked with the manufacturing of sustainable aviation fuel (SAF). With a thorough examination of the possible effects, this paper centers on Gevo's intended Net-Zero 1 (NZ1) alcohol-to---jet (ATJ) SAF facility in South Dakota. CRA's research shows that every dollar spent through fed... Continue Reading
Category: StocksTotal Views: 240 By : Caleb PriceUpdated: 08-10-2024
FDA Approves Neffy® Nasal Spray for Severe Allergic Reactions
Leading biopharmaceutical developer of treatments for severe allergic reactions, ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) reached a major turning point with FDA approval of neffy® (epinephrine nasal spray) 2 mg. Now approved for use in adults and children weighing 66 pounds or more experiencing Type I Allergic Reactions, including potentially fatal anaphylaxis, this novel treatment is First needle-free epinephrine delivery ... Continue Reading
Category: StocksTotal Views: 339 By : Riley HayesUpdated: 08-10-2024
Introduction to OneMedNet Corporation
Leading curating and managing of regulatory-grade Real World Data (RWD) is OneMedNet Corporation (Nasdaq: ONMD). By including its own artificial intelligence technology into its data curating procedures, the company has lately made a big advance. Along with simplifying the de-identification of patient data, this invention significantly cut running expenses. OneMedNet has improved its capacity to process enormous volumes of clinical data by using artificia... Continue Reading
Symbotic Expands Capabilities with Strategic Acquisition
Leader in A.I.-enabled robotics technology Symbolic Inc. (Nasdaq: SYM) has made a big advance by acquiring Veo Robotics' assets. This purchase seeks to improve Symbotic's capacity for field-based industrial automation innovation, especially in settings where humans and robots collaborate. By including Veo Robotics' FreeMove® 3D vision system, Symbolic will be able to guarantee worker safety while raising output. Bringing... Continue Reading